<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095610</url>
  </required_header>
  <id_info>
    <org_study_id>C-455</org_study_id>
    <nct_id>NCT05095610</nct_id>
  </id_info>
  <brief_title>Clinical Effects of Intermitent Continuous Glucose Monitoring in Type 1 Diabetes</brief_title>
  <official_title>Clinical Effects of Intermitent Continuous Glucose Monitoring (Flash) in Adult Patients With Type 1 Diabetes in an Spanish Public Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Castilla-La Mancha Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Castilla-La Mancha Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational cross-sectional multicenter study about clinical effect of intermitent&#xD;
      continuous glucose monitoring (Flash) in adult type 1 diabetes patients in an Spanish public&#xD;
      health system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational cross-sectional multicenter study about clinical effect of intermitent&#xD;
      continuous glucose monitoring (Flash) in adult type 1 diabetes patients in an Spanish public&#xD;
      health system.&#xD;
&#xD;
      All clinical variables are gathered from chart review. Data analysis is conducted using SPSS&#xD;
      statistic software. Results are presented as mean +/- SD values. A paired Student´s t-test or&#xD;
      Wilconxon signed test were used fr the analysis differences. Comparison between proportions&#xD;
      were analyzed using a chi-square test. A P value &lt;0.05 was considered statistically&#xD;
      significant.&#xD;
&#xD;
      The protocolo was apporved by the reference Castilla-La Mancha Public Health Service Ethic&#xD;
      Commitee. All participants provided written consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c difference</measure>
    <time_frame>1 year</time_frame>
    <description>Difference in HbA1c before initiating iCGM compared with HbA1c levels after one year of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of SBGM</measure>
    <time_frame>1 year</time_frame>
    <description>Daily number of blood capilary test fot glycemia determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Flash</measure>
    <time_frame>1 year</time_frame>
    <description>Time of use of Flash glucose monitoring (% possible time of use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIR</measure>
    <time_frame>1 year</time_frame>
    <description>Time in range (TIR, 3.9-10 mmol/L) of the interstitial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAR</measure>
    <time_frame>1 year</time_frame>
    <description>Time above range (TAR, &gt;10 mmol/L) of the interstitial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBR</measure>
    <time_frame>1 year</time_frame>
    <description>Time bellow range (TBR, &lt;3.9 mmol/L) of the interstitial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%CV</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of the variation coefficient (%, &gt;36% is considered high levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>1 year</time_frame>
    <description>Total corporal body weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>1 year</time_frame>
    <description>Daily insulin dose requirements (UI/Kg/d)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1121</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Adult Type 1 Diabetes</arm_group_label>
    <description>All adult patients with type 1 diabetes previously followed in the DIACAM study (see bellow reference).&#xD;
Sastre J, Pinés PJ, Moreno J, Aguirre M, Blanco B, Calderón D, Herranz S, Roa C, Lopez J; Grupo de estudio DIACAM 1. Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study. Endocrinol Nutr. 2012 Nov;59(9):539-46. doi: 10.1016/j.endonu.2012.07.003.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flash</intervention_name>
    <description>Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.</description>
    <arm_group_label>Adult Type 1 Diabetes</arm_group_label>
    <other_name>FreeStyle Libre</other_name>
    <other_name>iCGM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients &gt;18 years with type 1 diabetes and previously followed in the DIACAM study&#xD;
        (see reference).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of Type 1 diabetes.&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  Patients previously followed in the DIACAM study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other kinds of diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>La Mancha- Centro Hospital</name>
      <address>
        <city>Alcázar De San Juan</city>
        <state>Ciudad Real</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco Jose Gonzalez, MD</last_name>
      <phone>926580500</phone>
      <email>kikojosy@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Hospital</name>
      <address>
        <city>Puertollano</city>
        <state>Ciudad Real</state>
        <zip>13500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen de Altagracia Hospital</name>
      <address>
        <city>Valdepeñas</city>
        <state>Ciudad Real</state>
        <zip>13300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mercedes Palma, MD</last_name>
      <email>mercedespalmamoya@yahoo.es</email>
    </contact>
    <contact_backup>
      <phone>926320200</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virgen del Prado Hospital</name>
      <address>
        <city>Talavera De La Reina</city>
        <state>Toledo</state>
        <zip>45600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albacete University Hospital</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obispo Rafael Torija, St.</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guadalajara University Hospital</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandra Herranz, PhD</last_name>
      <phone>949209200</phone>
      <email>herranzantolin@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo University Hospital</name>
      <address>
        <city>Toledo</city>
        <zip>45007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Julia Sastre, PhD</last_name>
      <phone>900252525</phone>
      <email>jsastrem@sescam.jccm.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Sastre J, Pinés PJ, Moreno J, Aguirre M, Blanco B, Calderón D, Herranz S, Roa C, Lopez J; Grupo de estudio DIACAM 1. Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study. Endocrinol Nutr. 2012 Nov;59(9):539-46. doi: 10.1016/j.endonu.2012.07.003. Epub 2012 Oct 4. English, Spanish.</citation>
    <PMID>23039989</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>intermitent continous glucose monitoring</keyword>
  <keyword>Flash</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After approval for the rest ot investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

